Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib

from BiotechTV - News · host BiotechTV

He discusses learnings about durability, dosing, biomarkers, and more for this first-in-class target.

Episode metadata supplied by the publisher feed · Published Jan 28, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib

0:00 27:18

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 27 minutes long.

This episode was published on January 28, 2026.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!